Short Interest in VivoSim Labs, Inc. (NASDAQ:VIVS) Declines By 34.6%

VivoSim Labs, Inc. (NASDAQ:VIVS) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totaling 25,097 shares, a drop of 34.6% from the November 30th total of 38,358 shares. Based on an average trading volume of 44,418 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.0% of the shares of the stock are short sold. Currently, 1.0% of the shares of the stock are short sold. Based on an average trading volume of 44,418 shares, the days-to-cover ratio is currently 0.6 days.

VivoSim Labs Trading Down 6.0%

Shares of VIVS stock opened at $1.89 on Tuesday. The company has a market capitalization of $4.93 million, a price-to-earnings ratio of -0.43 and a beta of 1.27. The firm has a 50-day moving average price of $2.21 and a 200 day moving average price of $2.30. VivoSim Labs has a twelve month low of $1.41 and a twelve month high of $21.96.

VivoSim Labs (NASDAQ:VIVS) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.98) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million for the quarter. VivoSim Labs had a negative return on equity of 28.83% and a negative net margin of 1,413.57%.

Institutional Investors Weigh In On VivoSim Labs

A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP bought a new position in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs at the end of the most recent quarter. 8.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VivoSim Labs in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.